MRI

Societies host events for MR Safety Week

By AuntMinnie.com staff writers

Observances trace to the 2001 death of Michael Colombini.

July 27, 2026

Wellumio nabs $9.75M for portable stroke imaging device

By AuntMinnie.com staff writers

Axana is a portable, battery-powered brain imaging device that delivers MRI-based stroke assessment at the point of care.

July 23, 2026

Wellumio co-founders Dr Shieak Tzeng and Dr Sergei Obruchkov with the Axana portable stroke detection device.

MRI could replace DRE for prostate cancer staging

By Amerigo Allegretto

MRI showed comparable performance to DRE in prostate cancer staging without compromising patient outcomes.

July 15, 2026

Prostate Cancer 400

MRI shows higher neuro symptom burden for former football players

By Amerigo Allegretto

Former elite football players have lower white matter volume and report higher levels of depression and anxiety.

July 13, 2026

Voxel-based morphometry (VBM) group comparison of grey matter brain volumes. TFCE-corrected significance map shown (one-tailed t-test; higher significance indicated by light blue color). (a) Comparison between ex-soccer players (n = 124) and controls (n = 40). (b) Comparison between ex-rugby players (n = 200) and controls (n = 33) from Graham & Zimmerman et al. (2025), reproduced with permission under Creative Commons license.

Imagion extends collaboration with Siemens on MRI contrast agent

By AuntMinnie.com staff writers

Siemens will provide in-kind expertise and technical support to clinical sites.

July 8, 2026

Quibim launches AI breast MRI tool across Europe, UK

By AuntMinnieEurope.com staff writers

The tool, QP-Breast, highlights suspicious areas on MRI and generates reports from imaging findings.

July 2, 2026

Qp Breast Press 02

German MRI concept aims to transform pediatric imaging

By Claudia Tschabuschnig

Why pediatric MRI still means anesthesia for too many children and how the field is trying to change that.

June 17, 2026

As part of the KidsMRI project, children are to be introduced to the examination using age-appropriate training and support concepts, with the aim of enabling MRI scans to be performed more often without anesthesia in the future.

MRI: The third imaging 'window' happens after the exam

By Giuseppe Scappatura

Why the two minutes after a scan may be the most clinically important -- and the least automatable -- part of what radiographers do.

June 15, 2026

Giuseppe Scappatura of the Grande Ospedale Metropolitano Bianchi Melacrino Morelli in Reggio Calabria, Italy.

Experts propose new MRI standards for prostate cancer screening

By Kate Madden Yee

The guidance is intended to provide consensus on the acquisition, interpretation, and reporting of prostate MRI.

June 11, 2026

Am 2016 10 04 11 38 34 158 Prostate 400

AI gives a boost to cardiac MRI risk prediction

By Kate Madden Yee

Accurate risk prediction for coronary heart disease helps clinicians guide patient therapy and follow-up.

June 10, 2026

C-index for Cox regression and random survival forests models using two feature sets. Adding historical registry data decreases the C-index for Cox regression but increased it for the random survival forests model, consistent with the non-linear structure in the registry data.

SERAM 2026: Biparametric MRI cuts time and costs in prostate cancer imaging

By Claudia Tschabuschnig

A study presented at SERAM 2026 suggests that biparametric MRI (bpMRI) can reduce exam time and costs in patients with clinically significant prostate cancer.

June 8, 2026

Biparametric prostate MRI identified clinically significant Gleason 3+4 prostate cancer using T2-weighted imaging, diffusion-weighted imaging, and ADC mapping alone.

Image-guided focal laser ablation effective for prostate cancer

By Amerigo Allegretto

MRI-directed, ultrasound-guided TPLA may be a promising technique to treat prostate cancer while avoiding radical therapies.

June 3, 2026

Preablation, postablation, and recurrence multiparametric MRI scans depict a 63-year-old man treated with transperineal focal laser ablation (TPLA) for localized prostate cancer. Clinical parameters included an initial prostate-specific antigen (PSA) level of 7.2 ng/mL, a Prostate Imaging Reporting and Data System (PI-RADS) grade 4 lesion (red circles) in the right apical peripheral zone, and a maximum tumor length of 5 mm. MRI-guided targeted biopsy confirmed a Gleason score 3+4 prostate cancer tumor. (A) Pre-ablation axial T2-weighted MRI scan and apparent diffusion coefficient (ADC) image shows the apical PI-RADS 4 lesion (circles). (B) Six-month post-ablation axial T2-weighted MRI scan and ADC image show cystic necrosis (arrows). There was no evidence of recurrence; the PSA level was 1.5 ng/mL. (C) One-year after ablation, the patient’s PSA level had increased to 4.3 ng/mL. Axial T2-weighted MRI scan and the ADC image shows a recurrent lesion (blue circles) in the right apical peripheral zone adjacent to the ablation scar. Targeted biopsy confirmed Gleason score 3+4 prostate cancer, which was classified as in-field recurrence of clinically significant prostate cancer and subsequently re-treated with TPLA. In summary, serial multiplanar MRI demonstrates treatment response after TPLA with post-ablation necrosis, followed by MRI-detected IFR confirmed with biopsy at 12-month follow-up. Multiparametric MRI was performed with a 3.0-T MRI scanner (Skyra; Siemens Healthineers) using T2-weighted, diffusion-weighted, and ADC sequences, with gadobenate dimeglumine contrast material administration (Bracco Diagnostics).

Page 1 of 274